I just put £4k into my SIPP. Here’s where I’m going to invest it

The words

Investing in a SIPP (Self-Invested Personal Pension) is one of the best ways to build wealth for retirement in the UK. Not only are all gains income tax-free, but contributions are boosted by tax relief.

Last week, I put £4k into my SIPP in an effort to build my retirement savings. Here’s how I’m going to invest it.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Readers are responsible for carrying out their own due diligence and for obtaining professional advice before making any investment decisions.

An near-instant 25% return

Let me start by saying that I’ll have more than £4k to invest. Thanks to tax relief, I’ll receive another £1k in my account from the government in the next few months (a risk-free 25% return). So in total, I’ll have £5k to invest.

If I invest this well, this could grow to a large sum by the time I come to retire.

Today, I’m 44. If I was to generate a 9% return on that £5k for the next 20 years, it could be worth around £28k by the time I’m 64. If I was to keep growing it at 9% a year until I was 70, I could be looking at nearly £50k.

Where I’m investing

Now, I’m not going to invest this money all at once. I prefer to drip feed money into the markets over time (especially after they’ve had a great run).

However, one product I will put some money into right now is the Schroders Global Healthcare fund. There are two reasons why.

First, my portfolio is very tech-heavy at present. I want to diversify into other sectors to reduce my risk levels. Second, healthcare offers a nice mix of growth and defence, to my mind. If we were to see an economic slowdown, companies in this sector may provide some protection.

It’s worth noting that this fund returned 11% a year for the five years to the end of May. Past performance is not an indicator of future returns though.

A promising holding

One stock in the fund I’m really excited about is Novo Nordisk (NYSE:NVO). It’s the maker of GLP-1 weight-loss drugs Wegovy and Ozempic.

This company’s having a huge amount of success right now, thanks to its weight-loss drugs. This year, revenue’s forecast to grow 26% to $41bn.

I suspect the growth story here is just getting started. According to analysts at Barclays – who have called obesity drugs the healthcare ‘story of the decade’ – the industry could be worth $200bn annually by 2030 (versus $11bn in 2023).

Given the potential market size, some analysts believe these drugs could become one of the pharma industry’s biggest success stories.

It’s worth pointing out that Novo is facing competition from Eli Lilly, which also has weight-loss drugs on the market today. It could also face competition in the years ahead from Amgen and AstraZeneca, both of which are developing their own products.

The good news is that the Schroders Global Healthcare fund has a large position in Eli Lilly (at the end of May it was the largest holding while Novo Nordisk was the fifth-largest). So all my eggs aren’t in one basket.

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report — 5 Shares for the Future of Energy — and discover:

• Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
• How to potentially get paid by the weather
• Electric Vehicles’ secret backdoor opportunity
• One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

More reading

Edward Sheldon has positions in Novo Nordisk and the Scroders Global Healthcare fund. The Motley Fool UK has recommended AstraZeneca Plc, Barclays, and Novo Nordisk. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.